CLINICAL_TRIALS
research
· 2025-03-20
Clinical Trial Update: Efgartigimod for the Treatment of Guillain-Barré Syndrome [Phase 2, Phase 3]
Summary
This update notes that efgartigimod is in Phase 2 and Phase 3 trials for Guillain-Barré syndrome, with no recruitment yet.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Zhongming Qiu | Conditions: Guillain-Barre Syndrome (GBS) | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING